Your browser doesn't support javascript.
loading
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory.
Mendoza, Tito; Sheshadri, Ajay; Altan, Mehmet; Hess, Kenneth; George, Goldy; Stephen, Bettzy; Castillo, Lilibeth; Rodriguez, Enedelia; Gong, Jing; Peterson, Christine; Rodon Ahnert, Jordi; Fu, Siqing; Piha-Paul, Sarina A; Pant, Shubham; Dumbrava, Ecaterina; Yap, Timonthy A; Janku, Filip; Tsimberidou, Apostolia M; Subbiah, Vivek; Karp, Daniel D; Zarifa, Abdulrazzak; McQuinn, Lacey M; Cleeland, Charles; Hong, David S; Naing, Aung.
Afiliación
  • Mendoza T; Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA tmendoza@mdanderson.org.
  • Sheshadri A; Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Altan M; Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hess K; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • George G; Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Stephen B; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Castillo L; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rodriguez E; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gong J; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Peterson C; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rodon Ahnert J; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Fu S; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Piha-Paul SA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pant S; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Dumbrava E; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Yap TA; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Janku F; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Tsimberidou AM; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Subbiah V; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Karp DD; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Zarifa A; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • McQuinn LM; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Cleeland C; Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Hong DS; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Naing A; Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J Immunother Cancer ; 8(2)2020 10.
Article en En | MEDLINE | ID: mdl-33097611
INTRODUCTION: Immunotherapies have revolutionized the treatment of various cancers, but little is known about their symptomatic toxicity. Assessing these symptoms is best accomplished by asking the patients themselves. However, such reports are subjective and may face challenges as bonafide scientific data. Demonstrating the validity of symptom assessment tools, mainly through the reduction of measurement errors, has the potential to improve patient care if these tools are widely adopted. To that end, we present herein the psychometric properties of the Immunotherapy for Early-Phase Trials module of the MD Anderson Symptom Inventory (MDASI-Immunotherapy EPT) in patients receiving various immunotherapies in early phase trials at a major cancer center. METHODS: One hundred forty-five patients completed the inventory at baseline, with 85 of them also doing so after 9 weeks of treatment. The mean (±SD) age of the patients was 57.0±12.9 years. Also, 56% of the patients were women, 79% identified as white, and 49% had at least some college education. RESULTS: The internal consistency reliability of the MDASI-Immunotherapy EPT was excellent, as the Cronbach's alphas for all of its subscales were at least 0.88 (range 0.88-0.95). Known-group validity based on Eastern Cooperative Oncology Group performance status groupings was excellent at 9 weeks after the start of an immunotherapy trial for the MDASI-Immunotherapy EPT severity (effect size, 0.96) and interference (effect size, 0.82) subscales. We found substantial changes in the symptom items difficulty remembering (effect size, -0.85), fever and/or chills (effect size, -0.63), disturbed sleep (effect size, -0.52), diarrhea (effect size, -0.42), and swelling of hands, legs, or feet (effect size, -0.39). CONCLUSIONS: In conclusion, the MDASI-Immunotherapy EPT is a valid, reliable, and sensitive tool for measuring symptomatic toxicity.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psicometría / Índice de Severidad de la Enfermedad / Inmunoterapia Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psicometría / Índice de Severidad de la Enfermedad / Inmunoterapia Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: J Immunother Cancer Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido